Ditolylguanidine

Ditolylguanidine

SCHEMBL158674

Cc1ccccc1/N=C(\N)Nc1ccccc1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 18/20 1.00
GRIN2D O15399 14/20 1.00
GRIN3B O60391 14/20 1.00
GRIN1 Q05586 14/20 1.00
GRIN2A Q12879 14/20 1.00
GRIN2B Q13224 14/20 1.00
GRIN2C Q14957 14/20 1.00
GRIN3A Q8TCU5 14/20 1.00
MEN1 O00255 1/20 1.00
PABPC1 P11940 1/20 1.00
ALOX15 P16050 1/20 1.00
TSHR P16473 1/20 1.00
KMT2A Q03164 1/20 1.00
EBP Q15125 1/20 1.00
TMEM97 Q5BJF2 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ditolylguanidine SCHEMBL29364709 1.00 SIGMAR1 (1.00) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
Ditolylguanidine SCHEMBL80339 1.00 SIGMAR1 (1.00) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
Ditolylguanidine SCHEMBL3388414 1.00 SIGMAR1 (1.00) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
Ditolylguanidine SCHEMBL8862769 0.98 SIGMAR1 (0.97) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8873081 0.87 SIGMAR1 (1.00) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8875387 0.87 SIGMAR1 (0.78) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8874196 0.84 SIGMAR1 (0.81) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8873792 0.84 SIGMAR1 (1.00) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL14861883 0.83 SIGMAR1 (0.78) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A
Hydrochloric Acid SCHEMBL8874645 0.83 SIGMAR1 (1.00) SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12220771-B2 Flux and solder paste SENJU METAL INDUSTRY CO., LTD. (JP) 2025-02-11 US claimed
US-20230263797-A1 Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States UNM RAINFOREST INNOVATIONS (US) 2023-08-24 US claimed
WO-2023055751-A1 MIXED SOLVENT HYDROGEL SYSTEM FOR WOUND HEALING UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2023-04-06 WO claimed
US-11559763-B2 Regenerable solvent mixtures for acid-gas separation RESEARCH TRIANGLE INSTITUTE (US) 2023-01-24 US claimed
EP-3683005-B1 FLUX AND SOLDER PASTE SENJU METAL INDUSTRY CO (JP) 2022-01-26 EP claimed
US-20210146003-A1 A NOVEL METHOD TO IMPROVE ADHESIVE STRENGTH OF REVERSIBLE POLYMERS AND HYDROGELS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2021-05-20 US claimed
US-10843298-B2 Flux and solder paste SENJU METAL INDUSTRY CO., LTD. (JP) 2020-11-24 US claimed
EP-3683005-A1 FLUX AND SOLDER PASTE Senju Metal Industry Co., Ltd (JP) 2020-07-22 EP claimed
WO-2018232384-A1 A NOVEL METHOD TO IMPROVE ADHESIVE STRENGTH OF REVERSIBLE POLYMERS AND HYDROGELS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2018-12-20 WO claimed
WO-2018156883-A1 METHODS OF TREATMENT FOR CANCER, STEROL HOMEOSTASIS, AND NEUROLOGICAL DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-08-30 WO claimed
US-9839875-B2 Regenerable solvent mixtures for acid-gas separation RESEARCH TRIANGLE INSTITUTE (US) 2017-12-12 US claimed
WO-2016138135-A1 SIGMA-1 RECEPTOR MODULATORS FOR TREATING HUNTINGTON'S DISEASE TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2016-09-01 WO claimed
EP-2611518-B1 REGENERABLE IONIC LIQUID SOLVENTS FOR ACID-GAS SEPARATION RES TRIANGLE INST (US) 2016-08-24 EP claimed
EP-2611518-A1 REGENERABLE IONIC LIQUID SOLVENTS FOR ACID -GAS SEPARATION Research Triangle Institute (US) 2013-07-10 EP claimed
US-20130164199-A1 REGENERABLE SOLVENT MIXTURES FOR ACID-GAS SEPARATION RESEARCH TRIANGLE INSTITUTE 2013-06-27 US claimed
WO-2012031274-A1 REGENERABLE IONIC LIQUID SOLVENTS FOR ACID -GAS SEPARATION RESEARCH TRIANGLE INSTITUTE (US) 2012-03-08 WO claimed
EP-0461252-B1 THERMOPLASTIC ELASTOMERS BASED UPON CHLORINATED OR CHLOROSULFONATED POLYETHYLENE AND A CRYSTALLINE OLEFIN POLYMER DOW CHEMICAL CO (US) 1998-06-03 EP claimed
US-5230936-A Chlorinated polyethylene, a mercaptotriazine. crosslinking agent, acid acceptor DAISCO CO., LTD. (JP) 1993-07-27 US claimed
US-4687756-A DITHIOCARBAMOYL GROUP CONTAINING COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-08-18 US claimed
US-4288576-A BASIC MATERIAL HERCULES INCORPORATED (US) 1981-09-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263797-A1 Mammalian Hybrid Pre-Autophagosomal Structure HyPAS and Compositions and Methods for the Treatment of Coronavirus Infections and Related Disease States SARS1, SQSTM1, ATG4A SIGMAR1 2480/4885GRIN2D 3581/4885GRIN3B 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.